Form 4: Madrigal Director Exercises Options, Sells Shares

Madrigal Pharmaceuticals Director Rebecca Taub exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged trading plan.

Summary

• Rebecca Taub, a Director at Madrigal Pharmaceuticals, Inc. (MDGL), engaged in transactions involving the company's common stock.
• On January 9, 2026, she exercised a stock option to acquire 240 shares of common stock at an exercise price of $15.8 per share.
• Concurrently, she sold 40 shares of common stock at $545.79 per share.
• She also sold an additional 200 shares of common stock at a weighted average price of $551.242 per share, with prices ranging from $551.24 to $551.25.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on September 10, 2025.
• Following these transactions, her direct beneficial ownership stands at 455,589 shares of common stock.
• Additionally, 655,540 shares are indirectly beneficially owned through SQN, LLC, where she and her spouse are managing members, with beneficial ownership disclaimed except for pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and sales under a 10b5-1 plan). While sales reduce direct ownership, the pre-arranged nature and option exercise are standard compensation activities and do not inherently signal positive or negative company performance.

Positives

• The exercise of stock options indicates a director's confidence in the company's long-term value, as they are acquiring shares at a significantly lower price than the market value at the time of sale.

Negatives

• The sale of shares by a director, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it reduces their direct stake in the company.

Industry Context

This Form 4 filing details routine insider transactions, specifically a director's exercise of stock options and subsequent sale of shares. Such transactions are common for executives and directors as part of their compensation and personal financial planning, often executed under pre-arranged Rule 10b5-1 plans to avoid accusations of trading on material non-public information. It does not provide specific insights into Madrigal Pharmaceuticals' operational performance or broader industry trends.

Related Party Transactions

• Rebecca Taub and her spouse are managing members of SQN, LLC, which indirectly beneficially owns 655,540 shares of Madrigal Pharmaceuticals common stock. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, might be viewed with slight caution, though the overall impact is likely minimal given the routine nature and the director's continued significant direct and indirect holdings. The exercise of options demonstrates the director realizing value from their compensation package.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically a director's exercise of stock options and subsequent sale of shares under a pre-arranged Rule 10b5-1 plan. Such transactions are common and generally do not provide new material information about the company's operational performance or future prospects. The director maintains a substantial direct and indirect beneficial ownership. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate as it neither presents significant positive catalysts nor alarming negative signals.

Keywords

Madrigal Pharmaceuticals, MDGL, Rebecca Taub, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transactions